Aslan Pharms Stock Price, News & Analysis

ASLAN Pharmaceuticals (NASDAQ: ASLN) received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement of US$1.00. This notice covers the period from February 11 to March 25, 2022, where ASLN’s closing bid price did not meet this threshold for 30 consecutive business days. The company has until September 26, 2022, to regain compliance, which requires the stock to trade above US$1.00 for at least ten consecutive days. The notification does not immediately affect trading but highlights potential delisting risks.

ASLAN Pharmaceuticals (NASDAQ: ASLN) announced positive results from a Phase 1b trial of eblasakimab (ASLAN004) presented at the 2022 AAD Annual Meeting. The study demonstrated significant efficacy in patients with moderate-to-severe atopic dermatitis, with 61% reduction in Eczema Area and Severity Index (EASI) for the highest dose (600mg) and favorable safety profile. Dr. Andrew Blauvelt noted the unmet need for effective treatments in atopic dermatitis. ASLAN will proceed to a Phase 2b trial with topline results expected in H1 2023, signaling strong developmental momentum for eblasakimab.

ASLAN Pharmaceuticals (ASLN) reported financial results for Q4 and full-year 2021, showing operational cash use of US$34 million and a net loss of US$31.3 million. As of December 31, 2021, cash and equivalents totaled US$90.2 million, projected to fund operations through late 2023. The company is advancing its Phase 2b TREK-AD trial for eblasakimab in atopic dermatitis, with topline data expected in H1 2023. New CMO Alex Kaoukhov brings over 20 years of experience, aiming to enhance the clinical progression.

ASLAN Pharmaceuticals (NASDAQ: ASLN) has announced that key efficacy and safety data from its eblasakimab Phase 1b study will be presented at the 2022 American Academy of Dermatology Annual Meeting on March 26. This randomized, double-blinded, placebo-controlled study focused on treating adult patients with moderate-to-severe atopic dermatitis. Eblasakimab is a novel monoclonal antibody targeting the IL-13 receptor, with the potential to offer improved safety and efficacy profiles.

ASLAN Pharmaceuticals (NASDAQ: ASLN) has appointed Alex Kaoukhov, MD, as the new Chief Medical Officer, effective immediately. With over twenty years of experience in biopharma, including roles at Almirall, Allergan, and Novartis, Kaoukhov brings expertise in dermatology and immunology as ASLAN prepares for late-stage trials of eblasakimab for atopic dermatitis. He replaces Dr. Kenneth Kobayashi, who has left the company. ASLAN's CEO, Dr. Carl Firth, expressed confidence in Kaoukhov's leadership, especially as the company progresses with its innovative pipeline.

Oak Hill Bio, a clinical-stage therapeutics company, has launched to develop medicines for extremely preterm infants and rare autoimmune diseases. The company has acquired a pipeline of six investigational therapeutics from Takeda Pharmaceutical, including two clinical-stage and four preclinical-stage programs. The lead candidate, OHB-607, aims to improve outcomes in premature infants and has shown promising Phase 2 results. Oak Hill plans to advance its clinical studies in 2022 and includes experienced executives from Takeda to support its mission.

ASLAN Pharmaceuticals has initiated the Phase 2b TREK-AD study to assess eblasakimab (ASLAN004), a potential first-in-class monoclonal antibody targeting the IL-13 receptor, for adults with moderate-to-severe atopic dermatitis. This randomized, double-blind, placebo-controlled trial will include approximately 300 patients across 100 sites globally and evaluate four dosing regimens. Topline results are expected in the first half of 2023. The study builds on positive data from a prior proof-of-concept trial, aiming to provide a novel treatment option for patients.

ASLAN Pharmaceuticals (Nasdaq: ASLN) will host the second webinar in its A⁴ series on January 20, 2022, at 12:00 PM ET, focusing on Atopic Dermatitis (AD) and ASLAN004. Dr. April Armstrong, a leading expert in skin diseases, will present on key clinical study parameters affecting patient responses. The session will include insights on ASLAN004's unique mechanism targeting IL-13 receptor α1 to address inflammation in AD. A Q&A will follow. Registration details are available online.

ASLAN Pharmaceuticals (NASDAQ: ASLN) announced that data from the Phase 1b dose escalation study of ASLAN004 for atopic dermatitis will be presented at the 2022 Winter Clinical Dermatology Conference in Koloa, Hawaii, from January 14-19, 2022. This study involved 25 patients and focuses on the safety and efficacy of ASLAN004, a monoclonal antibody targeting the IL-13 receptor. The data will also be showcased at the MauiDerm Conference from January 24-28, 2022. ASLAN004 is being developed as a first-in-class treatment for moderate-to-severe atopic dermatitis.